Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of “Hold” from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been given a consensus rating of “Hold” by the twenty-four brokerages that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $58.70.

Several research analysts have commented on the company. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Finally, Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently made changes to their positions in the company. Sentry Investment Management LLC acquired a new stake in Moderna in the first quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB lifted its stake in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new position in Moderna during the fourth quarter valued at about $41,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 4.0 %

NASDAQ:MRNA opened at $25.19 on Thursday. The stock’s fifty day moving average is $31.10 and its two-hundred day moving average is $40.37. Moderna has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a market capitalization of $9.74 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.